Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 9/20 | 0.83 |
| ▸ | KDR | P35968 | 7/20 | 0.81 |
| ▸ | RET | P07949 | 3/20 | 0.80 |
| ▸ | BRAF | P15056 | 3/20 | 0.80 |
| ▸ | FLT1 | P17948 | 3/20 | 0.80 |
| ▸ | GSK3B | P49841 | 2/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | ABL1 | P00519 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | KIT | P10721 | 2/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.80 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.80 |
| ▸ | MAOA | P21397 | 2/20 | 0.80 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.80 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.80 |
| ▸ | TTK | P33981 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793192 | 1.00 | RAF1 (0.83) | RAF1KDRRETBRAFFLT1 | |
| Formamide SCHEMBL28340615 | 0.95 | RAF1 (0.79) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL3411566 | 0.92 | RET (0.81) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL10000735 | 0.92 | RAF1 (0.83) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL28948534 | 0.92 | RAF1 (0.83) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL29918250 | 0.91 | RAF1 (1.00) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL548133 | 0.91 | RAF1 (1.00) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL4609009 | 0.90 | BRAF (0.82) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL3407209 | 0.90 | RAF1 (0.80) | RAF1KDRRETBRAFFLT1 | |
| SCHEMBL4737847 | 0.90 | KDR (1.00) | RAF1KDRRETBRAFFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115068620-A | Pharmaceutical composition capable of reducing generation of arylamine impurities | 天津睿创康泰生物技术有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | Technische Universität München (DE) | 2025-01-07 | — | — | US | disclosed |
| CN-114767714-B | Nanometer preparation of alkynyl-modified sorafenib derivative and silver wrapped by pore material, preparation method and application thereof | 济南大学 | 2023-06-20 | — | — | CN | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1603879-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-18 | — | — | US | disclosed |
| WO-2004078128-A2 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | RAF1 925/4885KDR 2667/4885RET 2991/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | RAF1 3218/4885KDR 2930/4885RET 4746/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | RAF1 2495/4885KDR 1193/4885RET 4179/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | RAF1 1691/4885KDR 3355/4885RET 2858/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | RAF1 3650/4885KDR 2741/4885RET 4641/4885 |
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | UMPS, UNG, UFM1 | RAF1 983/4885KDR 3399/4885RET 963/4885 |
| US-20040229937-A1 | Substituted pyridine derivatives useful in the treatment of cancer and other disorders | CDK4, MKI67, TP53 | RAF1 761/4885KDR 135/4885RET 605/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | RAF1 2415/4885KDR 876/4885RET 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.